옛 화면은 좌우로 밀어 볼 수 있습니다.

Publications

Projects :
Published Dates :
Select All
In Vitro Metabolism of a New Cardioprotective Agent, KR-33028 in the Human Liver Microsomes and Cryopreserved Human Hepatocytes (FRONTIER)
Arch Pharm Res Vol 28, No 11, 1287-1292, 2005 [LINK]
2005-Domestic
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. (NRL)
Rapid Commun Mass Spectrom. 2005;19(18):2651-2658 [LINK]
2005-International
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism (NRL)
Clin Pharmacol Ther. 2005;78(2):191-201. [LINK]
2005-International
Diclofenac attenuates Wnt/b-catenin signaling in colon cancer cells by activation of NF-kB ()
FEBS Letters, 2005, 579/4213~4218 [LINK ]
2005-International
MDR1 Genetic Polymorphisms and Comparison of MDR1 Haplotype Profiles in Korean and Vietnameses Populations (NRL)
Ther Drug Monit, 2005; 27(4):531-535. [LINK]
2005-International
Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but by CYP2C19 genetic polymorphism (NRL)
Br J Clin Pharmacol, 2005, 59/552~563 [LINK]
2005-International
Genetic Polymorphism of CYP2C9 in a Vietnamese Kinh Population (NRL)
Ther Drug Monit, 2005, 27/208~210 [LINK]
2005-International
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro (NRL)
Xenobiotica, 2005, 35/27~38 [LINK]
2005-International
Identification of functional characterization of nover CYP2J2 variants: G312 variant cuases loss of enzyme catalytic activity (NRL)
Pharmacogenetics and Genomics, 2005, 15/105~113 [LINK]
2005-International
Lansoprazole enantiomer activates human liver microsomal SYP2C9 catalytic activity in a stereospecific and substrate-specific manner (NRL)
Drug Metab Dispos, 2005, 33/209~213 [LINK]
2005-International